- Benzinga Cannabis Daily
- Posts
- Curaleaf’s Struggles, Village Farms’ Growth & Trump’s DEA Picks Amid $13B Global Drug War
Curaleaf’s Struggles, Village Farms’ Growth & Trump’s DEA Picks Amid $13B Global Drug War
Is Curaleaf’s stock bottoming out or bouncing back? Plus, why Village Farms’ international growth might be its saving grace and Trump’s DEA shake-up.
You're receiving this email because you're subscribed to Cannabis Daily from Benzinga. To manage your subscription, click the link at the bottom of this email.
Hey there, happy Friday! It’s Nicolás Rodríguez and Patricio Liddle here, bringing you this week’s latest updates from the cannabis world. We’ll dive into Curaleaf’s struggles, Village Farms’ international prospects, and Advanced Flower Capital’s strong performance. Plus, we’ll unpack the drama surrounding President-elect Trump’s DEA pick, the U.S.’s $13 billion global drug war, and its impact. Lastly, if you're running a dispensary, we’ve got some holiday inventory tips to boost your profits. Let’s get into it!
After crashing 75% from its 2022 high of $8, Curaleaf stock is testing $1.70—its next support level. If $1.70 holds, maybe there’s a chance for a bounce, but don’t hold your breath. Without a game-changing catalyst, this one looks stuck. Resistance levels to watch: $2.50 and $3.00. But if that breaks, it’s likely back to $1.00. Tough times. Do you want to know if this is a buy or a hold? Check out Rolando Garcia’s full analysis for the inside scoop.
Village Farms shows signs of recovery with a 30-40% margin on branded sales and a growing footprint in Germany, Australia, and the UK. Despite a 1% growth in Canada, international sales are expected to drive future revenue. The stock is undervalued, trading at an enterprise value of $120 million, which analyst Pablo Zuanic argues doesn’t reflect the true value of its cannabis assets.
Meanwhile Advanced Flower Capital continues to outperform, delivering a 14% dividend yield with a quarterly payout of $0.33. In 2024, it secured $116 million in new loan commitments, including a $41 million facility to Story Cannabis in Maryland. Its portfolio diversification has reduced risk, and analysts predict continued growth in distributable earnings, with potential dividend hikes and an increase in BVPS from $9.91.
President-elect Trump’s DEA pick chaos feels like theater, but behind the curtain lies a more sobering act: the U.S.’s $13 billion spent on global “counternarcotics” since 2015.
A report by Harm Reduction International and the Drug Policy Alliance reveals how these taxpayer dollars have funded forced rehabilitation, toxic fumigation, and militarized drug wars in countries like the Philippines, Colombia, and Mexico—leaving devastation in their wake. The DEA’s role in these initiatives highlights a troubling commitment to colonialist, violent drug policies over evidence-based harm reduction.
As international communities suffer, the U.S. remains haunted by its domestic war on drugs. Charlamagne the God hit the nail on the head, calling out President Biden for pardoning his son but failing to release non-violent cannabis prisoners like Edwin Rubis, who’s served 27 years for weed offenses.
The hypocrisy is glaring: billions wasted abroad, lives destroyed at home, and promises still unfulfilled.
Did you know your U.S. taxes fund the global war on drugs? A new report from DPA and HRI shows how U.S. foreign assistance budgets have supported and expanded destructive and deadly anti-drug responses worldwide.
— Drug Policy Alliance (@DrugPolicyOrg)
3:55 PM • Dec 4, 2024
As Texas gears up to pass Senate Bill 3, aiming to ban all THC products, the state is looking to close a legal loophole exploited since 2019.
In Illinois, the state Supreme Court has approved searches based on the smell of raw cannabis, raising privacy concerns.
Meanwhile, Pennsylvania’s push for legalization could generate up to $2.8 billion in tax revenue and create 45,000 jobs in its first year. With numbers like these on the line, the stakes are high for cannabis businesses as the battle over legalization and prohibition intensifies.
Dispensary owners, now’s the time to rethink your inventory. Green Wednesday 2024 delivered massive sales, with average basket sizes jumping 91% from a normal Wednesday to $70.80. Flower sales saw a dip, but vapes (+28%) and edibles (+14%) spiked, proving consumers are after variety.
Offering discounts—38% off flowers, 35% off vapes, 28% off edibles, and 33% off pre-rolls—drove traffic and boosted sales. Markets like Ohio (+89%) and New Jersey (+27%) are on fire, while California (-8%) and Colorado (-9%) lag. New York saw top basket averages at $83.37. Smart stocking—focus on vapes, edibles, and pre-rolls—could maximize profits through the holiday season.
Weekend Weed Reads:
Will Hemp Clothing Ever Become Affordable? Here's What's Changing
Snoop Dogg Launches Online Cannabis Marketplace Featuring THCA Flower And Smoking Accessories
Cannabis-Focused Poseidon Bets On New Jersey, Wraps Up Investments In These Two Dispensaries
EXCLUSIVE: Why Teens Are Confused By Cannabis Products And How Parents Can Help
NFL Eases Marijuana Rules: Is Full Legalization In The Game Plan?
Aaron Rodgers Opens Up About Psychedelic Healing In New Netflix Docuseries, 'Enigma'
Stay ahead of the curve with our insider updates on cannabis stocks, trends, and policy shifts. Share if you found this valuable! Did a good friend forward this to you? Subscribe now!
Our Writers Today
Nicolás holds a B.A. in International Relations, an M.A. in International Affairs, and an M.Phil in Public Policy. He is a doctoral student in Public and Urban Policy at The New School in New York City. After working for the United Nations in 2014, Nico pivoted his research to studying the relationship between the cannabis industry and economic development.
Patricio is a development economist with extensive experience in IT, finance, and banking. He writes about the economic and social opportunities obscured by over half a century of failed drug prohibition. Beyond his professional expertise, Pato is a committed advocate for social change, passionately working to promote harm reduction and reform drug policies.
BEFORE YOU GO
Were you forwarded this email? Click here to subscribe.
And be sure to check out our other newsletters:
Ring The Bell: Created for market enthusiasts by market enthusiasts, this twice-daily newsletter delivers top stories, fast movers, and hot trade ideas straight to your inbox. Subscribe here.
Future Finance: Where fintech, crypto, and the future of finance collide. Future Finance is a perfect lunch read packed with quick bites for industry enthusiasts. Subscribe here.
Real Estate Weekly: Ready to elevate your real estate game? This weekly newsletter provides actionable insights whether you are investing in REITs, owning property, or delving into the fast-growing world of fractional real estate. Subscribe here.
Advisor: Tailor-made for Financial Advisors, this weekly newsletter has industry-specific insights, analysis, and news. Subscribe here.